Cytodyn Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
14
- Stock Symbol
-
CYDY
- Investments
-
4
- Share Price
-
$0.22
- (As of Friday Closing)
Cytodyn General Information
Description
CytoDyn Inc is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of its product candidate, leronlimab, which is being studied for its potential in solid-tumor oncology. Leronlimab targets CCR5, a receptor increasingly recognized for its role in tumor progression, metastasis and immune regulation, providing the company with the opportunity to explore a potentially differentiated therapeutic approach across multiple solid tumor indications. It operates as a single reporting segment, focused on the clinical development of leronlimab.
Contact Information
Website
www.cytodyn.comCorporate Office
- 1111 Main Street
- Suite 660
- Vancouver, WA 98660
- United States
Corporate Office
- 1111 Main Street
- Suite 660
- Vancouver, WA 98660
- United States
Cytodyn Timeline
Cytodyn Stock Performance
As of 20-Nov-2026, Cytodyn’s stock price is $0.22. Its current market cap is $326M with 1.47B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.22 | $0.23 | $0.18 - $0.40 | $326M | 1.47B | 1.97M | -$0.03 |
Cytodyn Financials Summary
As of 31-Aug-2026, Cytodyn has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Aug-2026 | FY 2026 31-May-2026 | FY 2025 31-May-2025 | FY 2024 31-May-2024 |
|---|---|---|---|---|
| EV | 342,530 | 426,608 | 432,409 | 185,796 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (54,998) | (40,450) | 8,029 | (44,294) |
| Net Income | (57,095) | (42,699) | 3,745 | (49,841) |
| Total Assets | 19,054 | 13,973 | 18,047 | 11,136 |
| Total Debt | 27,270 | 27,276 | 27,341 | 30,076 |
Cytodyn Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cytodyn Comparisons
Industry
Financing
Details
Cytodyn Competitors (21)
One of Cytodyn’s 21 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| iBio | Corporation | San Diego, CA | ||||
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
| GeoVax Labs | Corporation | Smyrna, GA | ||||
| VLPbio | Formerly VC-backed | Boecillo, Spain |
Cytodyn Patents
Cytodyn Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026198581-A1 | Compositions and methods of treating ccr5 positive cancers and immune exhaustion | Pending | 17-Mar-2025 | ||
| WO-2025250666-A1 | Methods of treating cancer and inflammation-related diseases with leronlimab | Pending | 29-May-2024 | ||
| US-20240392014-A1 | Aav-mediated expression of long-acting anti-ccr5 binding agents for the treatment and prevention of hiv | Pending | 02-Dec-2022 | ||
| US-20240392015-A1 | Long-acting anti-ccr5 binding agents for the prevention and treatment of hiv | Pending | 02-Dec-2022 | ||
| AU-2023288452-A1 | Methods of treating nafld and nash | Pending | 22-Jun-2022 | A61P1/16 |
Cytodyn Signals
Cytodyn Investments & Acquisitions (4)
Cytodyn’s most recent deal was a Merger/Acquisition with ProstaGene for . The deal was made on 16-Nov-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ProstaGene | 16-Nov-2018 | Merger/Acquisition | Diagnostic Equipment | ||
| Progenics Pharmaceuticals (Pro 140) | 30-Jul-2012 | Corporate Asset Purchase | Buildings and Property | ||
| Advanced Genetic Technologies | 30-Jan-2007 | Merger/Acquisition | Drug Discovery | ||
| Advanced Influenza Technologies | 21-Jul-2006 | Merger/Acquisition | Drug Discovery |
Cytodyn ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Cytodyn FAQs
-
When was Cytodyn founded?
Cytodyn was founded in 2002.
-
Where is Cytodyn headquartered?
Cytodyn is headquartered in Vancouver, WA.
-
What is the size of Cytodyn?
Cytodyn has 14 total employees.
-
What industry is Cytodyn in?
Cytodyn’s primary industry is Drug Discovery.
-
Is Cytodyn a private or public company?
Cytodyn is a Public company.
-
What is Cytodyn’s stock symbol?
The ticker symbol for Cytodyn is CYDY.
-
What is the current stock price of Cytodyn?
As of 20-Nov-2026 the stock price of Cytodyn is $0.22.
-
What is the current market cap of Cytodyn?
The current market capitalization of Cytodyn is $326M.
-
Who are Cytodyn’s competitors?
Ayala Pharmaceuticals, iBio, Dynavax Technologies, GeoVax Labs, and VLPbio are some of the 21 competitors of Cytodyn.
-
What is Cytodyn’s annual earnings per share (EPS)?
Cytodyn’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process